Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories
The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
The MAGiC catheter is designed for robotically-navigated cardiac ablation procedures
_256_384.jpg){kind=logo}
Fasting glucose improved by 12.3 mg/dL, while liver stiffness dropped 23.7%, signaling a direct hepatic benefit
WuXi Biologics has integrated sustainability principles throughout its supplier lifecycle management
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
Subscribe To Our Newsletter & Stay Updated
